Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and safety of standard dosing on peripheral blood CD34+ cell mobilization. Of 15 patients enrolled to date, only one was chronically transfused and ten were on hydroxyurea. Of eight patients who achieved a CD34+ cell concentration >30 cells/μL, six were on hydroxyurea. There was no clear dose response to increasing plerixafor dosage. There was a low rate of serious adverse events; two patients developed vaso-occlusive crises, at the doses of 80 μg/kg and 240 μg/kg.

Hydroxyurea may have contributed to the limited CD34+ mobilization by affecting baseline peripheral blood CD34 counts, which correlated strongly with peak peripheral blood CD34 counts. Plerixafor administration did not induce significant increases in the fraction of activated neutrophils, monocytes, or platelets. However, increased neutrophils positive for activated β2 integrin and Mac-1 were associated with serious adverse events. In summary, plerixafor was well tolerated but did not achieve consistent CD34+ cell mobilization in this cohort of patients, most of whom were being actively treated with hydroxyurea and only one was chronically transfused. The study will continue with escalation of the dose of plerixafor and modification of hydroxyurea administration.

Clinicaltrials.gov identifier: NCT02193191.
of the chemokine receptor CXCR4 and prevents binding of its ligand CXCL12 or stromal cell derived factor-1α to induce HPC mobilization.\textsuperscript{13} We hypothesized that plerixafor’s mechanism of action would lead to less marked increases in white blood cell (WBC) counts and therefore less cell loss and coagulation system activation in SCD and supported this with data from a pre-clinical study involving a sickle cell mouse model.\textsuperscript{14} Nevertheless, the safety of plerixafor in SCD patients remains a matter of concern because of possible activation of WBC and neutrophils which could still lead to vaso-occlusive complications and the risk of early death in SCD.\textsuperscript{16-19} As CXCR4 is expressed on most WBC and is involved in the retention of these cells in bone marrow, a standard dose of plerixafor of 240 μg/kg increases all major WBC subsets (neutrophils, lymphocytes, monocytes) in normal donors about 3- to 4-fold.\textsuperscript{20} Notably, however, in SCD patients who received G-CSF, not all patients who had highly elevated WBC counts experienced vaso-occlusive complications, and conversely, not all patients who experienced vaso-occlusive complications had highly elevated WBC counts,\textsuperscript{21} suggesting that WBC activation rather than WBC count \textit{per se} may contribute to vaso-occlusion in SCD.

Another issue of concern is whether enough peripheral blood CD34+ cells can be mobilized in SCD patients with plerixafor. The mean and median peak CD34+ counts using plerixafor alone in normal donors are only \textasciitilde 25/μL,\textsuperscript{13,20} SCD patients might mobilize particularly well, in that SCD patients might have increased circulating HPC even at steady state, although more so during a crisis.\textsuperscript{21,22} Furthermore, SS and Sβ° patients tend to be autosplenectomized, and data from patients with thalssemia showed that splenectomized patients mobilized about twice as many peripheral blood CD34 cells with plerixafor alone as non-splenectomized patients.\textsuperscript{23}

Another consideration when using plerixafor is whether to withhold hydroxyurea, the recommended standard of care for most SCD patients. Hydroxyurea may inhibit mobilization and withholding hydroxyurea for 2 weeks leads to a degree of spontaneous mobilization that abets drug-induced mobilization.\textsuperscript{25,24} However, Richard \textit{et al.} showed that two of the three SCD patients whose hydroxyurea was withdrawn for 2 weeks developed painful crises following the withdrawal. Given these considerations, we designed a prospective phase I dose escalation study of both the safety and efficacy of plerixafor in patients with SCD in which the patients continued on their standard outpatient treatment used for disease control. We have completed the dosing cohorts through to the standard plerixafor dose of 240 μg/kg and report the interim results here.

### Methods

#### Study design

This study is conducted under FDA IND 122657, registered in ClinicalTrials.gov as NCT02195191, and approved by the Institutional Review Boards of Memorial Sloan Kettering, Weill Cornell Medical College and the New York Blood Center. The study design is a 3 + 3 dose escalation study with six levels of escalation: doses of 80, 160, 240, 320, 400, and 480 μg/kg. There are two primary endpoints: (i) efficacy, defined by the achievement of a HPC mobilization level of 30 CD34+ cells/μL; and (ii) safety, defined by the occurrence of serious adverse events (≥ grade 3) that are at least possibly plerixafor-related (including vaso-occlusive events).

At any dose level, the occurrence of at least one grade 3 serious adverse event results in the addition of three more patients to the dose escalation study of both the safety and efficacy of plerixafor in patients with SCD in which the patients continued on their standard outpatient treatment used for disease control. We have completed the dosing cohorts through to the standard plerixafor dose of 240 μg/kg and report the interim results here.
Probability of escalation: 0.91 0.71 0.49 0.31 0.17 0.08

For the efficacy endpoint, the dose escalation will continue to 480 μg/kg unless all patients at a preceding dose level achieve a peripheral blood CD34+ concentration of at least 30 cells/μL. In the present dose-escalation phase, no leukapheresis is performed. If and when the efficacy endpoint is safely reached, the study will proceed to a leukapheresis phase (including preclinical transduction and editing) in three patients.

Eligible subjects are adults with SS or Sβ0 disease, normal renal and liver function, hemoglobin concentration ≥6 g/dL, WBC count ≥3,000/μL, absolute neutrophil count (ANC) ≥1,500/μL, and platelet count of ≥150,000/μL. Eligible subjects are admitted to the Clinical Research Center at Weill Cornell Medical College. A single subcutaneous injection of plerixafor (Sanofi-Genzyme) is administered in the evening between 8-9 pm. The protocol calls for peripheral blood sampling at three time points (baseline, 0-2 h prior to plerixafor; peak between 6-12 h after the plerixafor dose; at the presumed return to baseline between 20-24 h after the dose): for reasons of feasibility and patient comfort issues, the peak sample was consistently drawn at a mean of 12 ± 1 h after plerixafor administration and the return to baseline sample at a mean of 20 ± 0.29 h after the dose. Since patients have pre-existing anemia, for reasons of safety no more than a total of 105 mL of blood is drawn at all three time points combined.

Peripheral blood CD34 testing

Flow cytometric evaluation of the collected peripheral blood is performed using a FACS Canto flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) and FACS Diva software (BD Biosciences). Samples are stained and analyzed within 2-12 h of collection using a modification of the International Society of Hematotherapy and Graft Engineering (ISHAGE) method (see Online Supplementary Methods).

CD34^+CD38^- enumeration

Mononuclear cells are isolated from 2 mL peripheral blood by Ficoll-Hypaque Plus density centrifugation. CD34^+ cells are purified by positive selection (MidiMACS™ LS Columns, Miltenyi) and stained with CD34 (BD PharMingen) and CD38 (Invitrogen).

Research cell and coagulation activation studies

Peripheral blood samples drawn at baseline and after 12 h are stained within 1 h of collection for activation markers relevant to sickle vaso-occlusion and assessed by flow cytometry (BD FACSCanto™). For CD16b^+ (1D3, Beckman Coulter) neutrophils: activated β2 integrin (clone 24, abcam), activated Mac-1 (CBRM1/5, eBioscience), E-selectin-Fc chimera (724-ES, R&D Systems), L-selectin (DREG-56, eBioscience), Mac-1/CD11b (ICRF44, BD Pharmingen), and LFA-1/CD11a (HI111, BD Pharmingen). For CD14^+ (M5E2, BD Pharmingen) monocytes: tissue factor (HTF-1, BD Pharmingen). For CD41^+ (HiP2, BD Pharmingen) platelets: CD16b (1D3, Beckman Coulter) and CD14 (M5E2, BD Pharmingen). The percentages of positive cells and median fluorescent intensity (MFI) are assessed for each
Statistical analysis

Absolute concentrations as well as the fold increases (ratio of peak at 12 h to baseline absolute concentrations) of standard clinical as well as research parameters were analyzed. For patient B(2), to avoid computing correlations on an infinite value, we replaced the baseline value of 0 by 0.2 in the analyses using CD34+ ratio (10/0.2 = 50). When applying non-parametric statistics, the chosen value does not affect the results, as long as it is close to 0. The presence of a trend in increases of CD34+, ANC, and WBC counts (both at 12 h and fold increases) with increasing dose was tested using the non-parametric Cuzick test for trend. Correlations between baseline values, and values at 12 h or fold increases were estimated using the Kendall tau. A difference in the distribution of 12 h and fold increases according to the administration of hydroxyurea was investigated using a Wilcoxon test.

For analyses of cell activation and coagulation, Wilcoxon signed rank paired testing was performed on the combined dose cohorts for differences between 12 h and baseline values, whereas significant fold differences between dose levels was examined with the Kruskal-Wallis test. Correlations between values were estimated using the Kendall tau. Two-tailed \( p \) values <0.05 were considered statistically significant.

Results

Patients' characteristics

Fifteen subjects have been recruited to date for the study at the first three dose levels of 80, 160 and 240 \( \mu \)g/kg. Fourteen patients were enrolled from Montefiore Medical Center (New York, USA) and one patient from The Mount Sinai Hospital (New York, USA) (Table 1). Two patients enrolled at dose levels 1 and 2 were subsequently re-enrolled in the study at a higher plerixafor dose (dose level 3). All subjects had a past history of moderate to severe acute chest syndrome, defined by requiring treatment with simple or exchange transfusion. Importantly, for safety and feasibility, patients were continued on their standard outpatient treatment being used to control their disease. Ten of 15 patients were on hydroxyurea, with a median HbF level of 12.4% (Online Supplementary Table S1) and median baseline ANC of 4100/\( \mu \)L (Online Supplementary Table S2). Only one of the 15 subjects was receiving chronic transfusion therapy, with a HbF of 1.2% and HbA of 54%; this patient was also on deferasirox for the treatment of transfusion-related iron overload. HbA was absent in all other patients. In the non-transfused patients, HbF levels correlated strongly with hemoglobin concentration, hematocrit, and reticulocyte counts. Of nine patients for whom splenic imaging was available, seven had splenic atrophy (Online Supplementary Table S1).

Efficacy of CD34+ mobilization

Absolute WBC counts, neutrophil counts and CD34+ cell concentrations increased from baseline in all patients (Figure 1). Absolute monocyte and lymphocyte counts also increased from baseline (Online Supplementary Table S2). Our target goal of mobilizing at least 50 CD34+ cells/\( \mu \)L was, however, reached in only 50% of patients given the plerixafor dose of 80 \( \mu \)g/kg, 33% of patients given 160 \( \mu \)g/kg, and 35% of patients given 240 \( \mu \)g/kg. Peak ANC (\( p=0.03 \)) and WBC count (\( p=0.05 \)), but not CD34+ cell count (\( p=0.65 \)), increased with increasing dose level. As previously reported in healthy donors, \( 13,30,31 \) there was a strong correlation of peak CD34+ count with baseline CD34+ concentration (Kendall tau=0.68, \( p=0.0006 \)) but no correlation was observed with baseline ANC (Kendall tau=0.09, \( p=0.66 \)) or baseline WBC count (Kendall tau=0.13, \( p=0.49 \)) (Figure 2). There was also no correlation, as previously reported, \( 13,30,31 \) with baseline platelet count.
count (Kendall tau=0.30, P=0.13) or donor age (Kendall tau=0.14, P=0.49).

There was a significant increase in the median CD34+ fold increase with dose (P=0.01) (Online Supplementary Figure S1). A trend was observed for ANC ratio, although not statistically significant (1.6-, 1.8-, and 2.1-fold increases, P=0.08). No trend was seen for WBC ratio (P=0.13). With the caveat of statistical adjustment for patient 8(2)’s baseline CD34+ count of 0/μL, there was no correlation between CD34+ fold increase and baseline CD34+ (Kendall tau= -0.32, P=0.11), baseline ANC (Kendall tau=0.19, P=0.52), or baseline WBC (Kendall tau=0.22, P=0.25) (Online Supplementary Figure S2).

Hydroxyurea was not associated with differences in peak absolute CD34+ concentration (P=0.95), peak ANC (P=0.59) or peak WBC (P=0.68) concentrations (Figure 3); or with differences in the fold-increases of CD34+ cell concentrations (P=0.64), ANC (P=0.12), or WBC (P=0.36) concentrations (Online Supplementary Figure S3).

In a subset of six patients, CD34+CD38- cells were enumerated (Online Supplementary Table S3), showing a median 3-fold increase in CD34+CD38- concentrations at 12 h.

**Safety of plerixafor**

There were no significant changes in hemoglobin concentration, hematocrit, or platelet counts with plerixafor treatment (data not shown, baseline values in Online Supplementary Table S1). Due to the occurrence of one serious adverse event at the 80 μg/kg dose and another one at the 240 μg/kg dose, an additional three patients were enrolled at each of these dose levels. The serious adverse events were both pain crises, possibly related to plerixafor (Online Supplementary Table S4), but also associated with other possibly contributory events. Patient 13 with a serious adverse event had the second highest peak ANC (and third highest peak WBC count) in the study, but high WBC count and ANC were not consistently associated with serious adverse events.

There were no significant differences between dose levels for any of the activation markers of vaso-occlusion tested. With the exception of tissue factor-positive (TF+) monocytes at the 240 μg/kg dose, the median fold-changes in percentage of cells at every dose cohort were ≤1.1, arguing against generalized plerixafor-mediated cell activation (Figure 4A). Median fold increases in absolute numbers of activated β2 integrin-positive (αβ2+) neutrophils, activated Mac-1-positive (αMac-1+) neutrophils, and TF+ monocytes (160 μg/kg, 240 μg/kg) were close to 2 (Figure 4B). There were strong correlations between the fold increase in absolute numbers of neutrophils and fold increases in αβ2+ neutrophils (Kendall tau=0.85, P<0.001) and aMac-1+ neutrophils (Kendall tau=0.46, P=0.02). The absolute numbers of αβ2+ and aMac-1+ neutrophils were significantly increased (Online Supplementary Figure S4A,B), and the two patients with serious adverse events (gray arrows) had relatively high absolute numbers of αβ2+ and aMac-1+ neutrophils, albeit not the highest. There was also a significant increase in plasma prothrombin fragment 1.2 concentrations (Online Supplementary Figure S4C), but the two patients with serious adverse events had absolute concentrations and fold-increases at 12 h that were lower than the median and mean for that measure. Both patients with serious adverse events had relatively high fold-increases in L-selectin+ neutrophils and one had a large fold increase in TF+ monocytes (Figure 5), but their absolute numbers of L-selectin+ neutrophils and TF+ monocytes were not particularly high (Online Supplementary Figure S4D,E). There were significant decreases for five parameters: percentage of αβ2+ neutrophils, MFI of αβ2 neutrophils, percentage of TF+ monocytes, and percentage and absolute number of platelet-neutrophil aggregates (Online Supplementary Figure S5). There were no significant changes in the MFI of aMac-1+, Mac-1, LFA-1, or L-selectin on neutrophils (data not shown).

**Discussion**

Eight of 15 patients (53%) with SCD treated with plerixafor reached the peripheral blood CD34 cell target count of at least 30 CD34+ cells/μL, including three of six patients treated at a dose of 240 μg/kg. This is in contrast
with the findings of a recent study by Tisdale et al., in which mobilization was effective in seven of seven SCD subjects (100%) at a dose of 240 μg/kg.\textsuperscript{4} It should be noted that patients in the National Institutes of Health study were off hydroxyurea and had been transfused for at least 2 months to achieve a HbS <20-30%\textsuperscript{4,32} while in our study, ten of the 15 patients were on stable doses of hydroxyurea (for at least 1 year) and only one patient was on chronic transfusion. Although hydroxyurea, a ribonucleotide reductase inhibitor, causes myelosuppression and was recently found to reduce CD34 counts in peripheral blood and bone marrow,\textsuperscript{33} there is no definitive evidence that hydroxyurea negatively affects numbers or quality of cell cycle-quiescent hematopoietic stem cells or immature bone marrow progenitors as opposed to more mature myeloid-erythroid progenitors.\textsuperscript{33-37} Indeed, in our study, although we did not achieve consistent efficiency in CD34 cell mobilization, no correlation was found between hydroxyurea use, and absolute or fold increases in CD34+ cells/μL.\textsuperscript{4}

We observed wide inter-donor variability in CD34 mobilization with plerixafor, as previously reported in normal donors (CD34 peaks between 4-157/μL)\textsuperscript{13} and in patients with SCD (CD34 peaks between 50-200/μL).\textsuperscript{4} However, we also observed a strong correlation between baseline CD34+ and peak CD34+ concentrations, as previously reported with both G-CSF and plerixafor mobilization in healthy donors (Kendall tau=0.68, \textit{P}=0.0006).\textsuperscript{13,30,31} Factors contributing to baseline CD34 count remain unclear, but our data and others’ suggest that baseline CD34+ concentration may be affected by hydroxyurea-related myelosuppression.\textsuperscript{24,25} Patient #8, a subject re-enrolled in the study, was particularly instructive regarding this hypothesis. This patient was clinically stable on hydroxyurea at a dose of 27 mg/kg and was enrolled twice at an interval of 13 months. At the time of his second treatment, however, he had a markedly lower baseline ANC (1900/μL down from 6300/μL) and platelet count (217,000/μL down from 400,000/μL), probably related to oscillatory non-toxic hematopoiesis seen in SCD with chronic and dose-intensive treatment with hydroxyurea (ANC oscillations between 2,000-6,000/μL as determined from review of his clinical laboratory records).\textsuperscript{38} This myelosuppression was associated with a baseline CD34 concentration of 0/μL rather than 1/μL, possibly contributing to the relatively low 12 h CD34+ concentration of 10/μL at the 240 μg/kg dose as compared to 27/μL at the 160 μg/kg dose. In brief, because hydroxyurea can decrease ANC and platelet count,\textsuperscript{39} hydroxyurea-related myelosuppression may have contributed to the relatively poor CD34+ mobilization obtained in this cohort. However, avoiding hydroxyurea withdrawal might lower the risk of pain crises;\textsuperscript{24} we, therefore, plan to explore timing plerixafor administration to the peak rather than nadir of hydroxyurea-related oscillatory hematopoiesis. Finally with regards to hydroxyurea therapy, data from the six patients in whom we enumerated CD34+CD38– cells suggest that hydroxyurea may not adversely affect HSC, given that all patients except one (patient 10) were on hydroxyurea and a median 3-fold increase at 12 h was observed. Only 0.2-2.8% of CD34+ cells were CD38-negative, but this may be consistent with plerixafor’s effect in

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Fold changes in the percentage of cells expressing activation markers, according to plerixafor dose. (A) Other than % TF+ monocytes, median fold changes in % cells were ≤1.1. (B) Median fold changes in absolute number of cells for TF+ mono, aβ2+ PMN, and aMac-1+ PMN were closer to 2 than 1. Fold changes are ratios of 12 h to baseline values. Horizontal lines represent medians. Filled shapes represent hydroxyurea-treated patients, open shapes represent patients not treated with hydroxyurea. Gray arrows point to the values for the two SAE patients who had serious adverse events. TF+ mono: tissue-factor-positive monocytes; E-Selectin-positive neutrophils; aβ2+ PMN: activated β2 integrin-positive neutrophils, aMac-1+ PMN: activated Mac-1-positive neutrophils; L-Selectin-negative neutrophils; PMAs: platelet-monocyte aggregates; PNA: platelet-neutrophil aggregates.}
\end{figure}
normal healthy donors, in that fewer HPC may be mobilized by plerixafor than by G-CSF, where up to 50% of G-CSF-mobilized CD34+ cells are CD38-negative.\textsuperscript{15,40}

Because we enrolled only one patient on chronic transfusion, we cannot assess any correlation between transfusion and CD34 mobilization, although notably this patient had the second highest baseline and highest peak CD34+ cell counts in our study. Other studies of plerixafor in SCD\textsuperscript{3,24} have initiated chronic transfusion based on the hypothesis that the inflammatory nature of SCD affects the bone marrow and transfusion assuages bone marrow inflammation and stress erythropoiesis. Although replicative and oxidative stress of HPC in bone marrow may occur,\textsuperscript{41,42} there is limited evidence that HPC are damaged in SCD.\textsuperscript{36} Five of our patients had HbF-associated increases in hemoglobin concentration and hematocrit to more than 10 g/dL and 30%, respectively (similar to values in chronically transfused patients) but HbF levels did not correlate with CD34 cell mobilization.

Based on our data, it is possible that continued dose escalation could result in greater efficacy of mobilization, since we observed a dose-related response in the median CD34+ cell fold increase ($P=0.01$), as also observed in healthy donors.\textsuperscript{45} Patient 3, a repeat enrollment who had never been on hydroxyurea and was clinically stable, is instructive in that his 12 h peak CD34+ cell count following a plerixafor dose of 80 μg/kg was only 8/μL whereas at the dose of 240 μg/kg it was 40/μL, even though his baseline CD34+ cell concentrations (1/μL and then 2/μL) were similar, suggesting a dose-response to plerixafor. Notably, his two periods in the study were separated by 19 months, suggesting that, as with healthy donors,\textsuperscript{46} intra-individual CD34+ cell counts in stable SCD patients not on hydroxyurea may remain stable over time. Based on these data and given the safety and continued dose response between 240 μg/kg and 480 μg/kg observed in healthy donors,\textsuperscript{47} we plan to continue dose escalation in SCD patients through to the 480 μg/kg dose, barring significant adverse events. Adding the CXCR2 agonist, GROβ, might be useful.\textsuperscript{48}

Only two of 15 patients (13%) developed serious adverse events as compared to three of seven patients (43%) in the study of plerixafor mobilization in SCD by Tisdale et al.,\textsuperscript{4} although this must be qualified by the fact that the patients in the study by Tisdale et al. also underwent leukapheresis. Our low rate of serious adverse events could, however, also be due to chronic hydroxyurea therapy and the subsequent lower WBC and ANC peaks. As the fraction of activated neutrophils did not increase significantly with plerixafor, our low serious adverse event rate may be related to moderation of ANC elevations by hydroxyurea, reducing the absolute number of activated cells. Given the still uncertain risks of morbidity, as seen with G-CSF, the use of plerixafor in SCD requires further evaluation.

In summary, our present data suggest that, with regards the efficacy of CD34 mobilization, red blood cell transfusion may be more effective than continuing standard of care. Whether red blood cell transfusion will remain more effective as we escalate the plerixafor dose (as safety allows) to 480 μg/kg, with protocol revisions for hydroxyurea-treated patients, is unknown. Finally, potential candidates for SCD gene therapy may not be able to receive regular red blood cell transfusions (e.g. if they have red cell alloimmunization or a history of hyperhemolysis) or may not be willing to do so (e.g. Jehovah Witnesses), even for the relatively short duration of 2-3 months.

This study has several limitations. Firstly, despite this study being the largest study to date of plerixafor administration in SCD patients, overall the number of patients involved remains small; thus comparisons, for example, between hydroxyurea-treated and non-hydroxyurea-treated patients, may not be representative of the actual populations. Secondly, we measured WBC, ANC and CD34 mobilization in this study only at ~12 and ~20 h after plerixafor administration. It is possible that an initial peak could have occurred at an earlier time (6-9 h) after plerixafor and could, therefore, have been missed. Nevertheless, CD34 cell concentrations remain at ~70% of peak levels at 12 h.\textsuperscript{20,45,48} Our current study will be amended to include the addition of earlier post-plerixafor assessments. Thirdly, we determined peripheral blood CD34 cell mobilization in the 15 patients treated with plerixafor, without performing apheresis. However, there is a well-described correlation between peripheral blood CD34 cell concentration and the ultimate CD34 cell dose obtained after apheresis. It is possible that technical adjustments may be required for this equation in the context of SCD. Finally, other than enumerating CD34+CD38- cells, we did not further characterize CD34+ cells to study stemness,\textsuperscript{32} for example by determining glycophorin A positivity and CD34 dimness.\textsuperscript{49} CD34+ or CD34+CD38- enumeration is not specific for HSC\textsuperscript{49} and it is, therefore, unclear whether patients had a true increase in HSC, as opposed to more mature lineage-committed CD34+ progenitors, which are either mobilized or present in bone marrow.\textsuperscript{50} We plan to characterize the CD34+ cells further as we move forward in the study, which is currently enrolling at the 320 μg/kg dose level. Despite mobilization of HSC possibly being less efficient with plerixafor than with G-CSF, plerixafor-mobilized HSC may have an engraftment advantage over G-CSF-mobilized HSC with regard to better retention of CXCR4, which facilitates homing.\textsuperscript{51}

Acknowledgments

The authors would like to thank our study subjects for their participation; the Doris Duke Charitable Foundation for a 2011 Innovation in Clinical Research Award for trial support (to PAS and MS); Sanofi-Genzyme for provision of plerixafor; Jena Simon for referring one study patient; W. Beau Mitchell for assistance with platelet activation studies; and Henny Billett, Narla Mohandas, and Beth Shaz for departmental support.

References

1. Mansilla-Soto J, Riviere I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol. 2011;154(6):715-727.

2. Rubèl JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848-855.

3. Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med. 2008;8(7):690-697.

4. Tisdale JF, Pierciey Jr. JF, Kanter J, et al. Successful Plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease. Blood. 2017;130(Suppl 1):190.

5. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individ-
19. Platt OS, Espy LT Jr, Mg weighted G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7): 679-694.

20. Cella, G., Marchetti, M., Vignoli, A., et al. Blood oxidative status and selects plasma levels in healthy donors receiving granulocyte-colony stimulating factor. Leukemia. 2006;20(6): 1450-1454.

21. de Haas M, Weert J, van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994;94(4): 3583-3591.

22. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hematotic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93(5): 2566-2571.

23. Canales MA, Arreta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res. 2002;11(4): 675-681.

24. Chiarandini N, Caron A, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell disease. Blood Cells Mol Dis. 2005;35(5): 384-388.

25. Maranou D, Carvalho G, Carvalho V, et al. Single-dose intravenous gamma globulin can stabilize neutrophil Mac-1 activation in sickle cell disease. Am J Hematol. 2015;90(5): 361-365.

26. Cattanà AA, Pronka RE, Franco-Ponteado CE, et al. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by sunitinib. Haematologica. 2011;96(4): 526-533.

27. Wu T, Styles L, DeCastro L, et al. Phase I study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One. 2014;9(7):e101501.

28. Nur E, van Beers EJ, Martina S, et al. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46(5): 138-145.

29. de la Rubia J, Lorenzo JI, Torrabadella M, al. Hematopoietic stem cell mobilization for cell activation or brain vaso-occlusion. Blood. 2017;129: 809-809.

30. Martino D, Chen G, Carullo V, et al. Basal neutrophil and monocyte colony-stimulating factor administration. A randomized controlled trial. Thromb Haemost. 2011;105(4): 655-662.

31. Canales MA, Arreta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res. 2002;11(4): 675-681.

32. Zhao J, Ma L, Vranova D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7): 801-813.

33. Schoeder MA, Pettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129(19): 2687-2692.

34. Choi E, Branch C, Cui MH, et al. Neutrophils, platelets, and inflammatory markers in healthy donors after administration of granulocyte colony-stimulating factor administration. A randomized controlled trial. Thromb Haemost. 2011;105(4): 2506-2514.

35. Steinberg MH, Barton F, Castro O, et al. A randomized controlled trial on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3): 600-609.

36. Lammoglia CE, Longo JJ, Torcson L, et al. Mobilization of hematopoietic progenitors in the bone of patients with sickle cell disease appear to be endogeneously mobilized. Br J Haematol. 2000;111(2): 491-497.

37. Yanekki A, Papayanopoulou T, Jonin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult stem cell target? Cytotherapy. 2009;11(4): 464-473.

38. Baird JH, Minniti CP, Lee JM, et al. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. Br J Haematol. 2015;166(5): 773-776.

39. Zuberi J, Nisen P, French C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57(9): 2306-2316.

40. Movva N, Frank N, French C, Fritsch G. Increased risk of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57(9): 2306-2316.

41. Dallalio G, Brunson CY, Means RT, Jr. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Invest Med. 2007;55(2):69-74.

42. Rotella MP, Sandro RA, Concan N, et al. Telomere length correlates with disease severity and inflammation in sickle cell disease. Rev Bras Hematol Hemoter. 2017;39(2):140-145.

43. Winkle LB, Broxmeyer HE, Rodgers E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2005;102(8): 2727-2730.

44. Emdenscheink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 15 months. Cytotherapy & Cell Cryom. 2012;14(21):18-25.

45. Hoggatt J, Singh P, Tate TA, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1-2):191-204.e10.

46. Lemory SJ, Hishe MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilization activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153(1):66-75.

47. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;335(6069):218-221.

48. Castro O, Nouraei M, Oneal P. Hydroxy-carbamidation treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014;167(5):697-701.

49. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130(15):1597-1599.

50. Drasar ER, Jiang J, Gardner K, et al. Leucocyte telomere length in patients with sickle cell disease. Br J Haematol. 2014;165(2):252-265.

51. Baird JH, Minniti CP, Lee JM, et al. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. Br J Haematol. 2015;166(5):773-776.

52. Zuberi J, Nisen P, French C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57(9): 2306-2316.

53. Dallalio G, Brunson CY, Means RT, Jr. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Invest Med. 2007;55(2):69-74.

54. Rotella MP, Sandro RA, Concan N, et al. Telomere length correlates with disease severity and inflammation in sickle cell disease. Rev Bras Hematol Hemoter. 2017;39(2):140-145.

55. Winkle LB, Broxmeyer HE, Rodgers E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2005;102(8): 2727-2730.

56. Emdenscheink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 15 months. Cytotherapy & Cell Cryom. 2012;14(21):18-25.

57. Hoggatt J, Singh P, Tate TA, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1-2):191-204.e10.

58. Lemory SJ, Hishe MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilization activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153(1):66-75.

59. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;335(6069):218-221.